Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLC

Nature Reviews Clinical Oncology

Volumn 6, Issue 9, 2009, Pages 499-500

  Rasul, Kakil Ibrahim ^a   Kerr, David J ^b  

^a Al Amal Hospital   (Qatar)

^b SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG MECHANISM; DRUG TARGETING; HUMAN; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PRIORITY JOURNAL; RASH; SEPSIS; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VINBLASTINE;

EID: 70450189505     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.108     Document Type: Article

References (10)

1. Pirker, R. et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLeX): an open-label randomised phase III trial. Lancet 373, 1525-1531 (2009).
2. Rosell, R. et al. Randomized phase ii study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in eGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol. 19, 362-369 (2008).
3. Lynch, T. J. et al. Overall survival (Os) results from the phase iii trial BMs 099: cetuximab+taxane/carboplatin as 1st-line treatment for advanced NSCLC. J. Thorac. Oncol. 3, S305 (2008).
4. Herbst, R. S. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. 22, 785-794 (2004).
5. Gatzemeier, U. et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25, 1545-1552 (2007).
6. van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009).
7. Tsao, M. S. et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133-144 (2005).
8. Eberhard, A. et al. Mutations in the epidermal growth factor receptor and in KRAs are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909 (2005).
9. Khambata-Ford, S. et al. K-RAs mutations and EGFR-related markers as potential predictors of cetuximab benefit in 1st line advanced NSCLC: results from the BMS-099 study, J. Thorac. Oncol. 3, S304 (2008).
10. Gatzemeter, V. et al. FLEX: cetuximab in combination with platinum-based chemotherapy improves survival versus CT alone for NSCLC. J. Thorac. Oncol. 3, S265 (2008).